dr. (Maiwenn) MJ Al

Associate Professor Erasmus School of Health Policy & Management Health Technology Assessment (HTA)

Location: Burg. Oudlaan 50, Rotterdam
Telephone: 010408556
Email: al@eshpm.eur.nl

Profile

Maiwenn Al obtained her Master degree in Mathematics at Leiden University in 1991. Since 1992 she has been working at the institute for Medical Technology Assessment (iMTA) at Erasmus University Rotterdam. From 1996 to 1999 she held a Pfizer Health Economics Fellowship and in 2001 she obtained her PhD degree at the Erasmus University Rotterdam. Her research focuses on modelling studies and methods for dealing with uncertainty in economic evaluations. Together with Ben van Hout, Maiwenn developed the cost-effectiveness acceptability curve, now widely used as a method to describe uncertainty around ICERs. Her most current research focuses on methods for censored data, including applications in the area of mental health care, and budget…

- - - M.S. Holleman, M.J. Al, R. Zaim, H.J.M. Groen & C.A. de Uyl-de Groot (2019). Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. The European Journal Of Health Economics. doi: 10.1007/s10198-019-01117-3
    - N.C. Büyükkaramikli, M.P.M.H. Rutten - van Molken, J.L. Severens & M.J. Al (2019). A verification checklist to reduce errors in models and improve their credibility. Value in Health, 37 (11), 1391-1408. doi: 10.1007/s40273-019-00844-y
    - R.A. Vremans, J. Geenen, A.M. Hovels, W. Goettsch, H.G.M. Leufkens & M.J. Al (2019). Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy. doi: 10.1007/s40258-019-00496-1 [go to publisher's site]
    - N.C. Buyukkaramikli, M.P.M.H. Rutten - van Molken, J.L. Severens & M.J. Al (2019). TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. Pharmacoeconomics (Print). doi: 10.1007/s40273-019-00844-y
    - M.S. Holleman, H. van Tinteren, H.J.M. Groen, M.J. Al & C.A. Uyl - de Groot (2019). First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Oncotargets and Therapy, 12, 1413-1421. doi: 10.2147/ott.S189438
    - E. Alemao, M.J. Al, A.A. Boonen, M.D. Stevenson, S. Verstappen, K. Michaud, M.E. Weinblatt & M.P.M.H. Rutten - van Molken (2018). Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS One (print), 13 (10). doi: 10.1371/journal.pone.0205013
    - N.C. Buyukkaramikli, S. de Groot, R. Riemsma, D. Fayter, N. Armstrong, P. Portegijs, S. Duffy, J. Kleijnen & M.J. Al (2018). Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0708-4
    - M.G. Franken, I. Corro Ramos, J. Los & M.J. Al (2018). The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. BMC Family Practice, 19 (31). doi: 1186/s12875-018-0714-9 [go to publisher's site]
    - E. Alemao, S. Johal, M.J. Al & M.P.M.H. Rutten - van Molken (2018). Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. Value in Health, 21 (2), 193-202. doi: 10.1016/j.jval.2017.05.020
    - N.C. Büyükkaramikli, S. de Groot, D. Fayter, R. Wolff, N. Armstrong, L. Stirk, G. Worthy, F.G. Albuquerque de Almeida, J. Kleijnen & M.J. Al (2017). Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. Pharmacoeconomics (Print). doi: 10.1007/s40273-017-0581-6
    - N. Büyükkaramikli, H.M. Blommestein, R. Riemsma, N. Armstrong, F.J. Clay, J. Ross, G. Worthy, J.L. Severens, J. Kleijnen & M.J. Al (2017). Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics (Print).
    - I. Corro Ramos, G.A.K. van Voorn, P. Vemer, T. Feenstra & M.J. Al (2017). A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data. Value in Health, 20 (8), 1041-1047. doi: 10.1016/j.jval.2017.04.016
    - L.T. Burgers, W.K. Redekop, M.J. Al, S.K. Lhachimi, N. Armstrong, S. Walker, C. Rothery, M. Westwood & J.L. Severens (2016). Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. European Journal of Health Economics (HEPAC), 1-12. doi: 10.1007/s10198-016-0824-z
    - H.M. Blommestein, N. Armstrong, S. Ryder, S. Deshpande, G. Worthy, C. Noake, R. Riemsma, J. Kleijnen, J.L. Severens & M.J. Al (2016). Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. Pharmacoeconomics (Online), 34 (1), 23-31. doi: 10.1007/s40273-015-0318-3
    - I. Corro Ramos, S. Lhachimi, A. Gerber-Grote & M.J. Al (2016). Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework. Medical Decision Making. doi: 10.1177/0272989X16636856
    - J. Bindels, B. Ramaekers, I. Corro Ramos, L. Mohseninejad, S. Knies, J. Grutters, M. Postma, M.J. Al, T. Feenstra & M. Joore (2016). Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. Pharmacoeconomics (Print), 34 (3), 315-322. doi: 10.1007/s40273-015-0346-z
    - P. Vemer, I. Corro Ramos, G.A.K. van Voorn, M.J. Al & T. Feenstra (2016). AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users. Pharmacoeconomics (Print), 34 (4), 349-361. doi: 10.1007/s40273-015-0327-2
    - R. Riemsma, I. Corro Ramos, R. Birnie, N.C. Buyukkaramikli, N. Armstrong, S. Ryder, S. Duffy, G. Worthy, M.J. Al, J.L. Severens & J. Kleijnen (2016). Integrated sensor-augmented pump therapy system [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technology Assessment, 20 (17). doi: 10.3310/hta20170
    - E. Alemao, H. Cawston, F. Bourhis, M.J. Al, M.P.M.H. Rutten - van Molken, K.P. Liao & D. Solomon (2016). Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. Rheumatology, 55 (5), 809-816. doi: 10.1093/rheumatology/kev427
    - E. Alemao, S. Joo, H. Kawabata, M.J. Al, P.D. Allison, M.P.M.H. Rutten - van Molken, M.L. Frits, C.K. Iannaccone, N.A. Schadik & M.E. Weinsblatt (2016). Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. Arthritis Care & Research, 68 (3), 308-317. doi: 10.1002/acr.22678
    - K.M. Goor, J.G. Gaultney, P. van Houten, A.S. Wagg, S.A. Huygens, M.M. Nielen, C.P. Albers-Heitner, W.K. Redekop, M.P.M.H. Rutten - van Molken & M.J. Al (2015). Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. PLoS One (print), 10 (10). doi: 10.1371/journal.pone.0138225
    - N. Armstrong, L.T. Burgers, S. Deshpande, M.J. Al, R. Riemsma, S.R. Vallabhaneni, P. Holt, J.L. Severens & J. Kleijnen (2015). The use of fenestrated and branched endovascular aneurysm repairfor juxtarental and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 18 (70). doi: 10.3310/hta18700
    - O. Mandrik, I. Corro Ramos, S. Knies, M.J. Al & J.L. Severens (2015). Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. Cancer Management and Research (online), 2015 (7), 279-289. doi: 10.2147/CMAR.S79258
    - I. Corro Ramos, M.P.M.H. Rutten - van Molken & M.J. Al (2015). Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis. Value in Health, 18 (1), 100-109. doi: 10.1016/j.jval.2014.09.003.
    - P. Whiting, M.J. Al, L.T. Burgers, M. Westwood, S. Ryder, M. Hoogendoorn, N. Armstrong, A. Allen, J.L. Severens & J. Kleijnen (2014). Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 18 (8). doi: 10.3310/hta18180
    - P. Vemer, P.F.M. Krabbe, T.L. Feenstra, G.A.K. van Voorn, I. Corro Ramos & M.J. Al (2013). Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force. Value in Health, 16, 1106-1107. doi: 10.1016/j.jval.2013.06.015
    - M. Hoogendoorn, M.J. Al, K.M. Beeh, D. Bowles, J.M.G. von der Schulenburg, J. Lungershausen, B. Monz, H. Schmidt, C. Vogelmeier & M.P.M.H. Rutten - van Molken (2013). Cost-effectiveness of triotropium versus salmeterol: the POET-COPD trial. European Respiratory Journal, 41 (3), 556-564. doi: 10.1183/09031936.000.27212
    - P. Vemer, M.J. Al, M. Oppe & M.P.M.H. Rutten - van Molken (2013). A Choice That Matters? Simulation study on the impact of direct meta-analysis methods on health economic outcomes. Pharmacoeconomics (Print), 31 (8), 719-730. doi: 10.1007/s40273-013-0067-0
    - M.A. Kiel, E. Roder, R. Gerth van Wijk, M.J. Al, W.C.J. Hop & M.P.M.H. Rutten - van Molken (2013). Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. Journal of Allergy and Clinical Immunology, 132, 353-360. doi: 10.1016/j.jaci.2013.03.013
    - L. Hakkaart-van Roijen, T.J.E.M. Bakker, M.J. Al, J. van der Lee, H.J. Duivenvoorden, M.W. Ribbe & R. Huijsman (2013). Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme. Bmc Health Services Research, 13 (370), 1-13. doi: 10.1186/1472-6963-13-370
    - M.J. Al (2013). Cost-Effectiveness Acceptability Curves Revisited. Pharmacoeconomics (Print), 31 (2), 93-100. doi: 10.1007/s40273-012-0011-8
    - M. Hoogendoorn, M.J. Al, K.M. Beeh, D. Bowles, J.M. Graf von der Schulenburg, J. Lungershausen, B. Monz, H. Schmidt, C. Vogelmeier & M.P.M.H. Rutten - van Molken (2013). Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. European Respiratory Journal. doi: 10.1183/09031936.00027212
    - M.R.C. Hendriks, M.J. Al, M. Bleijlevens, J.C.M. van Haastregt, H.F.J.M. Crebolder, J.T.M. van Eijk & S.M.A.A. Evers (2013). Continuous versus intermittent data collection of health care utilization. Medical Decision Making, 33, 998-1008. doi: 10.1177/0272989X13482045
    - I. Corro Ramos, M.P.M.H. Rutten - van Molken & M.J. Al (2013). The role of value-of-information analysis in a health care research priority setting: a theoretical case study. Medical Decision Making, 33 (4), 472-489. doi: 10.1177/0272989X12468616
    - I. Corro Ramos, M.P.M.H. Rutten - van Molken & M.J. Al (2012). The Role of Value-of-Information Analysis in a Health Care Research Priority Setting: A Theoretical Case Study. Medical Decision Making. doi: 10.1177/0272989X12468616
    - M. Oppe, M.J. Al & M.P.M.H. Rutten - van Molken (2011). Comparing Methods of Data Synthesis. Pharmacoeconomics (Print), 29 (3), 239-250. doi: 10.2165/11539870-000000000-00000
    - E.J.I. Hoogendoorn, M.P.M.H. Rutten - van Molken, R.T. Hoogenveen, M.J. Al & T.L. Feenstra (2011). Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. Value in Health, 14 (8), 1039-1047. doi: 10.1016/j.jval.2011.06.008
    - E. Alemao, S. Rajagopalan, R.E. Curiel, J. Purvis, S. Yang & M.J. Al (2011). Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma. Journal of Medical Economics, 14 (2), 245-252. doi: 10.3111/13696998.2011.566296
    - M.J. Al, L. Hakkaart-van Roijen, S.S. Tan & J. Bakker (2010). Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands. Critical Care, 14 (195), 1-10. doi: 10.1186/cc9313
    - L.M.A. Goossens, B. Standaert, N.G. Hartwig, A.M. Hovels & M.J. Al (2009). Conclusions on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. Vaccine, 27, 2531-2532. doi: 10.1016/j.vaccine.2009.02.036
    - L. Hakkaart-van Roijen, P. Verboom, R. Philips & M.J. Al (2009). The cost utility of solifenacin in the threatment of overactive bladder. International Urology and Nephrology, 41, 293-298. doi: 10.1007/s11255-008-9448-2
    - B. van den Berg, M.J. Al, N.J.A. van Exel, M.A. Koopmanschap & W.B.F. Brouwer (2008). Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers. Value in Health, 11 (7), 1041-1050. doi: 10.1111/j.1524-4733.2008.00357.x
    - M.J. Al, N. Maniadakis, E.W.M. Grijseels & M. Janssen (2008). Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands. Value in Health, 11 (4), 589-599. doi: 10.1111/j.1524-4733.2007.00303.x
    - S.S. Tan, L. Hakkaart-van Roijen, M.J. Al, C.A.M. Boumans, M.E. Hoogendoorn, P.E. Spronk & J. Bakker (2008). A microcosting study of intensive care unit stay in the Netherlands. Journal of Intensive Care Medicine, 23 (4), 250-257. doi: 10.1177/0885066608318661
    - L.M.A. Goossens, B. Standaert, N.G. Hartwig, A.M. Hovels & M.J. Al (2008). The cost-utility of rotavirus vaccination with Rotarix TM (RIX4414) in the Netherlands. Vaccine, 26, 1118-1127. doi: 10.1016/j.vaccine.2007.11.070
    - C.M. Galani, M.J. Al, H. Schneider & F.F.H. Rutten (2008). Uncertainty in decision-making: value of additional information in the cost-effectivenss of lifestyle intervention in overweight and obese people. Value in Health, 11 (3), 424-434. doi: 10.1111/j.1524-4733.2007.00284.x
    - J.B. Oostenbrink, M.J. Al, M. Oppe & M.P.M.H. Rutten - van Molken (2008). Expected value of perfect information: An Empirical example of reducing decision uncertainty by conducting additional research. Value in Health, 11, 1070-1080. doi: 10.1111/j.1524-4733.2008.00389.x
    - J. Lamers, R. Stupp, M.J. van den Bent, M.J. Al, T. Gorlia, J. Wasserfallen, N. Mittmann, S. Seung, R. Crott & C.A. de Uyl-de Groot (2008). Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cancer, 112 (6), 1337-1344.
    - C.A.M. Boumans, A. Lintsen, M.J. Al, C. Verhaak, M.J.C. Eijkemans, J.D.F. Habbema, D.D.M. Braat & L. Hakkaart-van Roijen (2008). Absence from work and emotional stress in woman undergoing IVF or ICSI: An analysis of IVF-related absence from work in women and the contribution of general and emotional factors. Acta Obstetricia et Gynecologica Scandinavica, 87, 1169-1175. doi: 10.1080/00016340802460305
    - L.M. Lamers, R. Stupp, M.J. van den Bent, M.J. Al, T. Gorlia, J. Wasserfallen, N. Mittmann, S. Seung, R. Crott & C. Groot (2008). Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme - A report from the EORTC 26981/22981 NCI-C CE3 intergroup study. Cancer, 112 (6), 1337-1344. doi: 10.1002/cncr.23297
    - B. van der Berg, M.J. Al, W. Brouwer, N.J.A. van Exel & M.A. Koopmanschap (2005). Economic valuation of informal care: The conjoint measurement method applied to informal caregiving. Social Science & Medicine, 61 (6), 1342-1355. doi: 10.1016/j.socscimed.2005.01.029
    - M.J. Al, T.L. Feenstra & B.A. van Hout (2005). Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. Health Economics, 14 (7), 655-667. doi: 10.1002/hec.973
    - J.B. Oostenbrink & M.J. Al (2005). The analysis of incomplete cost data due to dropout. Health Economics, 14 (8), 763-776. doi: 10.1002/hec.966
    - P. Sendi, M.J. Al & H. Zimmermann (2004). A risk-adjusted approach to comparing the return on the investment in health care programs. International Journal of Health Care Finance and Economics, 4, 199-210.
    - P. Sendi, M.J. Al & M. Battegay (2004). Optimising the performance of an outpatient setting. Swiss Medical Weekly, 134, 44-49.
    - M.J. Al & W.B.F. Brouwer (2004). Decision makers views on health care objectives and budget constraints; results from a pilot. Health Policy, 70, 33-48. doi: 10.1016/j.healthpol.2004.01.009
    - J.B. Oostenbrink, M.P.M.H. Rutten - van Molken, M.J. Al, J.A. Noord & W. van Vincken (2004). One-year cost-effectiveness of tiotropium to treat chronic obstructive pulmonary disease. European Respiratory Journal, 23, 241-249. doi: 10.1183/09031936.03.00083703
    - H.J. Bernelot Moens, J.J. Croonenborg, M.J. Al & P.M. Bemt (2004). Richtlijn 'NSAID-gebruik en preventie van maagschade'. Nederlands Tijdschrift voor Geneeskunde, 148, 604-608.
    - P. Sendi, M.J. Al, A. Gafni & S. Birch (2004). Portfolio theory and the alternative decision rule of cost- effectiveness analysis: theoretical and practical considerations. Social Science & Medicine, 58, 1853-1855. doi: 10.1016/j.socscimed.2004.01.001
    - P. Sendi, M.J. Al & F.F.H. Rutten (2004). Portfolio theory and cost- effectiveness analysis: A further discussion. Value in Health, 7, 595-601. doi: 10.1111/j.1524-4733.2004.75010.x
    - J.B. Oostenbrink, M.J. Al & M.P.M.H. Rutten - van Molken (2003). Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics (Print), 21, 1103-1112. doi: 10.2165/00019053-200321150-00004
    - P. Sendi & M.J. Al (2003). Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty. Social Science & Medicine, 57, 969-974. doi: 10.1016/S0277-9536(02)00477-X
    - P. Sendi, M.J. Al, A. Gafni & S. Birch (2003). Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. Social Science & Medicine, 57, 2207-2215. doi: 10.1016/S0277-9536(03)00086-8
    - C. Chevat, B.M. Pena, M.J. Al & F.F.H. Rutten (2001). Health care resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics (Print), 19 (1), 17-32.
    - H. Suryapranata, J.P. Ottervanger, E. Nibbering, A.W.J. van 't Hof, J.C.A. Hoorntje, M.F. de Boer, M.J. Al & F. Zijlstra (2001). Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. Heart, 85 (6), 667-671.
    - M.J. Al & B.A. van Hout (2000). A bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. Health Economics, 9, 599-609.
    - M.J. Al, M.A. Koopmanschap, P.J. van Enckevort, A. Geertsma, W. van der Bij, W.J. Boer & E.M. ten Vergert (1998). Coast- effectiveness of lung transplantation in the Netherlands. Chest, 113 (1), 124-130.
    - P.J. van Enckevort, E.M. TenVergert, G.J. Bonsel, A. Geertsma, W. van der Bij, W.J. Boer, M.A. Koopmanschap, M.J. Al & F.F.H. Rutten (1998). Technology Assessment of the Dutch lung transplantation program. International Journal of Technology Assessment in Health Care, 14 (2), 344-356.
    - M.J. Al, B.A. van Hout, C.M. Bowine & F.F.H. Rutten (1998). Sample size calculation in economic evaluations. Health Economics, 7, 327-335.
    - N.F. de Keizer, G.J. Bonsel, M.J. Al & R.J.B.J. Gemke (1998). The relation between TISS and real paedeatric ICU costs: a case study with generalizable methodology. Intensive Care Medicine, 24, 1062-1069. doi: 10.1007/s001340050717
    - B.C. Michel, M.J. Al, W.J. Remme, J.H. Kingma, J.A. Kragten, R. van Nieuwenhuizen & B.A. van Hout (1996). Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands. European Heart Journal, 17 (May), 731-740.
    - M.J. Al, B.C. Michel & F.F.H. Rutten (1996). The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis. Pharmacoeconomics (Print), 10 (2), 141-151.
  - - M.J. Al & W.B.F. Brouwer (2004). Stimuleren doelmatig gebruik van zuurpompremmers in de onderhoudsbehandeling. TSG, 82, 191-195.
    - I. Buijt, M.J. Al & F.F.H. Rutten (2003). Protonpompremmers, kostenremmers? . Pharmaceutisch Weekblad, 138, 1428-1429.
    - I. Buijt, M.J. Al & F.F.H. Rutten (2003). Protonpompremmers, kostenremmers? Pharmaceutisch Weekblad, 138, 1194-1199.
    - J.R.B.J. Brouwers, E.N. van Roon, M. Postma & M.J. Al (2000). Kosteneffectiviteit van NSAID's - Altijd gastoprotectie? Pharmaceutisch Weekblad, 135 (5), 172-175.
    - H.J. Stoevelaar & M.J. Al (1995). Medische statistiek; over getallen die leven en worden geleefd. Klinische Fysica, 1 (1), 25-29.
- - - P. Whiting, M.J. Al, M. Westwood, I. Corro Ramos, S. Ryder, N. Armstrong, K. Misso, J. Ross, J.L. Severens & J. Kleijnen (2016). Viscoelastic point-of-care testing to assist with the diagnosis management and monitoring of haemostasis a systematic review and cost-effectiveness analysis. (Extern rapport, 19, no 58). : Health Technology Assessment
    - R. Riemsma, M.J. Al, I. Corro Ramos, S.N. Deshpande, N. Armstrong, Y.C. Lee, S. Ryder, C. Noake, M. Krol, M. Oppe, J. Kleijnen & J.L. Severens (2013). SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis. (Extern rapport). Southampton: National Institute for Health Research
  - - M. Westwood, M.J. Al, L.T. Burgers, W.K. Redekop, S.K. Lhachimi, N. Armstrong, H. Raatz, K. Misso, J.L. Severens & J. Kleijnen (2013). A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD. (Extern rapport, 17, no 9). United Kingdon: Health Technology Assessment
    - M. Hoogendoorn, M.P.M.H. Rutten - van Molken, R. Hoogeveen, M.J. Al & T.L. Feenstra (2010). Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic, dynamic, population model for COPD. (Intern rapport). Rotterdam: iBMG
  - - M.J. Al (1995). Hulpambulances nader beschouwd. (Extern rapport). Den Haag: Begeleidingscommissie experiment hulpambulancevervoer
- - M.J. Al (2000). Modelleren en omgaan met onzekerheid. In M.P.M.H. Rutten- van Mölken, J.J. van Busschbach & F.F.H. Rutten (Eds.), Van kosten tot effecten (pp. 107-122). Maarssen: Elsevier gezondheidszorg
- - M.J. Al (2001, oktober 11). Certain methods for uncertain situations. Evaluating health care technologies. EUR Prom./coprom.: Dr. B.A. van Hout & prof.dr. F.F.H. Rutten.
- - E. Alemao (2018, juni 13). Future Economic Evaluations in Rheumatoid Arthritis : a case for considering comprehensive benefits and costs of interventions. EUR Prom./coprom.: Prof. Dr. M.P.M.H. Rutten-van Mölken & dr. M.J. Al.
  - C.M. Galani (2009, februari 12). Health Technology Assessment of Medical Interventions in the Prevention and Treatment of Disease DIrections of Further Research and Policy Implications. EUR (193 pag.) (Rotterdam) Prom./coprom.: prof.dr. F.F.H. Rutten & dr. M.J. Al.
  - M.J.C. Nuijten (2003, maart 26). In search for more confidence in health economic modeling: reducing uncertainty associated with modeling studies. EUR (208 pag.) Prom./coprom.: prof.dr. F.F.H. Rutten & dr. M.J. Al.
Advanced Research Methods
Title
Advanced Research Methods
Year
2019
Year level
(master - jaar 1)
Advanced Research Methods
Title
Advanced Research Methods
Year
2019
Year level
(master)
Health Technology Assessment
Title
Health Technology Assessment
Year
2019
Year level
(master) (master) (master)
Master Thesis HEPL
Title
Master Thesis HEPL
Year
2019
Year level
(master)
Advanced Health Economic Modelling
Title
Advanced Health Economic Modelling
Year
2019
Year level
(master) (master) (master)
Health Technology Assessment (Eu-HEM)
Title
Health Technology Assessment (Eu-HEM)
Year
2019
Year level
(master)
Advanced Health Economic Modelling EuHEM
Title
Advanced Health Economic Modelling EuHEM
Year
2019
Year level
(master)
Master Thesis HE
Title
Master Thesis HE
Year
2019
Year level
(master) (master)
Associate Professor
University
Erasmus University Rotterdam
School
Erasmus School of Health Policy & Management
Department
Health Technology Assessment (HTA)
Country
The Netherlands
Telephone
010408556
Value in Health Co-Editors
Role
Co-Editor
Start date approval
May/2012
End date approval
May/2016

Address

Visiting address

Burg. Oudlaan 50 3062 PA Rotterdam

Postal address

Postbus 1738 3000 DR Rotterdam

dr. (Maiwenn) MJ Al

More information

Profile

All publications (87)

Article (77)

Scholarly Publication (72)

Professional Publication (5)

Report (5)

Scholarly Publication (2)

Professional Publication (2)

Other Publication (1)

Part of book - Chapter (1)

Doctoral thesis (1)

Supervised Theses (3)

Teaching (8)

Present position

Associate Professor

Other positions (1)

Value in Health Co-Editors

Address

Visiting address

Postal address